Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran.
作者信息
Arai M
出版信息
J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):137-8. doi: 10.1136/jnnp.74.1.137.
Abstract
摘要
相似文献
1
Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran.与5-羟色胺和去甲肾上腺素再摄取抑制剂米那普明相关的帕金森综合征。
J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):137-8. doi: 10.1136/jnnp.74.1.137.
2
Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.米那普明和帕罗西汀治疗后抑郁症患者出现的治疗后新发不良事件。
Hum Psychopharmacol. 2004 Dec;19(8):585-6. doi: 10.1002/hup.644.
3
Levomilnacipran (Fetzima) a new SNRI for depression.左旋米那普明（Fetzima），一种用于治疗抑郁症的新型5-羟色胺-去甲肾上腺素再摄取抑制剂。
Med Lett Drugs Ther. 2013 Dec 23;55(1432):101-2.
4
Milnacipran and selective serotonin reuptake inhibitors in major depression.米那普明与选择性5-羟色胺再摄取抑制剂治疗重度抑郁症
Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:41-6. doi: 10.1097/00004850-199609004-00006.
5
Raynaud's syndrome in a patient treated with milnacipran.使用米那普明治疗的患者出现雷诺氏综合征。
Ann Pharmacother. 1999 Sep;33(9):1009-10. doi: 10.1345/aph.18402.
6
[Serotonin-noradrenaline reuptake inhibitors(SNRIs)].[5-羟色胺-去甲肾上腺素再摄取抑制剂（SNRIs）]
Nihon Rinsho. 2001 Aug;59(8):1523-9.
7
Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.米那普明与三环类抗抑郁药治疗重度抑郁症患者的比较研究：临床试验结果总结
Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:35-9. doi: 10.1097/00004850-199609004-00005.
8
Efficacy and tolerability of milnacipran: an overview.米那普明的疗效与耐受性：综述
Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:47-51. doi: 10.1097/00004850-199609004-00007.
9
Possible interaction between milnacipran and warfarin potassium.米那普明与华法林钾之间可能存在的相互作用。
J Clin Pharmacol. 2012 May;52(5):780-1. doi: 10.1177/0091270011398244.
10
Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.米那普明，一种新型5-羟色胺和去甲肾上腺素再摄取抑制剂：其抗抑郁活性及临床耐受性概述
Int Clin Psychopharmacol. 1997 Mar;12(2):99-108. doi: 10.1097/00004850-199703000-00005.
引用本文的文献
1
Association between anxiety disorder, anxiolytic drugs, and risk of incident Parkinson's disease.焦虑症、抗焦虑药物与帕金森病发病风险之间的关联。
NPJ Parkinsons Dis. 2025 Aug 21;11(1):252. doi: 10.1038/s41531-025-01104-x.
2
Respecting the Patient's Choice: A Case of Possible Drug-Induced Parkinsonism.尊重患者的选择：一例疑似药物性帕金森综合征病例
Pharmacy (Basel). 2022 Jan 4;10(1):10. doi: 10.3390/pharmacy10010010.
3
Sertraline-induced Hemichorea.舍曲林诱发的偏侧舞蹈症。
Tremor Other Hyperkinet Mov (N Y). 2017 Dec 18;7:518. doi: 10.7916/D8XK999F. eCollection 2017.
4
Parkinsonism secondary to duloxetine use: a case report.度洛西汀所致帕金森综合征：一例报告
North Clin Istanb. 2015 Dec 25;2(3):243-246. doi: 10.14744/nci.2015.63634. eCollection 2015.
5
Drug-induced parkinsonism in the elderly: incidence, management and prevention.老年人药物性帕金森病：发病率、治疗和预防。
Drugs Aging. 2012 Feb 1;29(2):105-18. doi: 10.2165/11598540-000000000-00000.
6
Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan.日本对米那普仑（日本首个 5-羟色胺和去甲肾上腺素再摄取抑制剂）的应用经验。
Neuropsychiatr Dis Treat. 2007 Feb;3(1):41-58. doi: 10.2147/nedt.2007.3.1.41.
Zotero 插件